Monopar Therapeutics
Monopar Therapeutics
MNPR
NASDAQ
32.61
USD
5.53%
About
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages.
The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers.
Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 259.3K |
| Three Month Average Volume | 1.4M |
| High Low | |
| Fifty-Two Week High | 8.65 USD |
| Fifty-Two Week Low | 1.3695 USD |
| Fifty-Two Week High Date | 23 Feb 2024 |
| Fifty-Two Week Low Date | 27 Nov 2023 |
| Price and Volume | |
| Current Price | 2.39 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -34.80% |
| Thirteen Week Relative Price Change | -26.92% |
| Twenty-Six Week Relative Price Change | -51.48% |
| Fifty-Two Week Relative Price Change | -40.95% |
| Year-to-Date Relative Price Change | 18.65% |
| Price Change | |
| One Day Price Change | 0.84% |
| Thirteen Week Price Change | -21.78% |
| Twenty-Six Week Price Change | -46.65% |
| Five Day Price Change | -7.00% |
| Fifty-Two Week Price Change | -26.01% |
| Year-to-Date Price Change | 40.51% |
| Month-to-Date Price Change | -31.70% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.87452 USD |
| Book Value Per Share (Most Recent Quarter) | 1.73003 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.87452 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.73003 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.40634 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.039 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.31461 USD |
| Normalized (Last Fiscal Year) | -3.039 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.039 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.31461 USD |
| Including Extraordinary Items (Last Fiscal Year) | -3.039 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.31461 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.43755 USD |
| Cash Per Share (Most Recent Quarter) | 2.02217 USD |
| Cash Flow Per Share (Last Fiscal Year) | -99999.99 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.07835 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.19038 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -10.80% |
| Tangible Book Value (5 Year) | -4.18% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 40.26% |
| EPS Change (Trailing Twelve Months) | 39.31% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -7,118,770 |
| Net Debt (Last Fiscal Year) | -7,266,080 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 7 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -7,858,290 |
| Free Cash Flow (Trailing Twelve Months) | -6,817,930 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -81.69% |
| Return on Assets (Trailing Twelve Months) | -81.33% |
| Return on Assets (5 Year) | -54.07% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -107.19% |
| Return on Equity (Trailing Twelve Months) | -102.31% |
| Return on Equity (5 Year) | -60.61% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -107.13% |
| Return on Investment (Trailing Twelve Months) | -102.31% |
| Return on Investment (5 Year) | -60.60% |